S100P is an early developmental marker of pancreatic carcinogenesis

Kenoki Ohuchida, Kazuhiro Mizumoto, Takuya Egami, Hiroshi Yamaguchi, Kei Fujii, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, Masao Tanaka

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Purpose: Our goal was to clarify the involvement and clinical significance of S100P in pancreatic carcinogenesis. Experimental Design: We examined S100P expression in 45 bulk pancreatic tissues; in microdissected cells, including invasive ductal carcinoma (IDC) cells (20 sections), pancreatic intraepithelial neoplasia (PanIN) cells (12 sections), intraductal papillary mucinous neoplasm (IPMN) cells (19 sections), and normal epithelial cells (11 sections); and in pancreatic juice samples from 99 patients with pancreatic diseases (32 cancer, 35 IPMN, and 32 chronic pancreatitis samples). We used quantitative real-time reverse transcription-PCR with gene-specific priming to measure S100P in these various types of samples. Results: In bulk tissue analyses, pancreatic cancer and IPMN expressed significantly higher levels of S100P than did nonneoplastic pancreas (P < 0.017 and P = 0.0013, respectively). Microdissection analyses revealed that IPMN expressed significantly higher levels of S100P than did IDC (P < 0.0001) and PanIN (P = 0.0031), although S100P expression did not differ between IDC and PanIN (P = 0.077). In pancreatic juice analyses, cancer and IPMN juice expressed significantly higher levels of S100P than did pancreatitis juice (both P < 0.0001). Receiver operating characteristic curve analyses revealed that measurement of S100P in pancreatic juice was useful for discriminating neoplastic disease from chronic pancreatitis (area under the curve = 0.837; 95% confidence interval, 0.749-0.903). Conclusion: S100P may be an early developmental marker of pancreatic carcinogenesis, and measurement of S100P in pancreatic juice may be useful for early detection of pancreatic cancer or screening of early pancreatic carcinogenesis.

Original languageEnglish
Pages (from-to)5411-5416
Number of pages6
JournalClinical Cancer Research
Volume12
Issue number18
DOIs
Publication statusPublished - Sep 15 2006

Fingerprint

Carcinogenesis
Pancreatic Juice
Neoplasms
Ductal Carcinoma
Chronic Pancreatitis
Pancreatic Neoplasms
Early Detection of Cancer
Pancreatic Ductal Carcinoma
Pancreatic Diseases
Microdissection
ROC Curve
Pancreatitis
Reverse Transcription
Area Under Curve
Pancreas
Research Design
Epithelial Cells
Confidence Intervals
Polymerase Chain Reaction
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

S100P is an early developmental marker of pancreatic carcinogenesis. / Ohuchida, Kenoki; Mizumoto, Kazuhiro; Egami, Takuya; Yamaguchi, Hiroshi; Fujii, Kei; Konomi, Hiroyuki; Nagai, Eishi; Yamaguchi, Koji; Tsuneyoshi, Masazumi; Tanaka, Masao.

In: Clinical Cancer Research, Vol. 12, No. 18, 15.09.2006, p. 5411-5416.

Research output: Contribution to journalArticle

Ohuchida, K, Mizumoto, K, Egami, T, Yamaguchi, H, Fujii, K, Konomi, H, Nagai, E, Yamaguchi, K, Tsuneyoshi, M & Tanaka, M 2006, 'S100P is an early developmental marker of pancreatic carcinogenesis', Clinical Cancer Research, vol. 12, no. 18, pp. 5411-5416. https://doi.org/10.1158/1078-0432.CCR-06-0298
Ohuchida, Kenoki ; Mizumoto, Kazuhiro ; Egami, Takuya ; Yamaguchi, Hiroshi ; Fujii, Kei ; Konomi, Hiroyuki ; Nagai, Eishi ; Yamaguchi, Koji ; Tsuneyoshi, Masazumi ; Tanaka, Masao. / S100P is an early developmental marker of pancreatic carcinogenesis. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 18. pp. 5411-5416.
@article{f4cb55e5edb54c02bff8da627f6f7e55,
title = "S100P is an early developmental marker of pancreatic carcinogenesis",
abstract = "Purpose: Our goal was to clarify the involvement and clinical significance of S100P in pancreatic carcinogenesis. Experimental Design: We examined S100P expression in 45 bulk pancreatic tissues; in microdissected cells, including invasive ductal carcinoma (IDC) cells (20 sections), pancreatic intraepithelial neoplasia (PanIN) cells (12 sections), intraductal papillary mucinous neoplasm (IPMN) cells (19 sections), and normal epithelial cells (11 sections); and in pancreatic juice samples from 99 patients with pancreatic diseases (32 cancer, 35 IPMN, and 32 chronic pancreatitis samples). We used quantitative real-time reverse transcription-PCR with gene-specific priming to measure S100P in these various types of samples. Results: In bulk tissue analyses, pancreatic cancer and IPMN expressed significantly higher levels of S100P than did nonneoplastic pancreas (P < 0.017 and P = 0.0013, respectively). Microdissection analyses revealed that IPMN expressed significantly higher levels of S100P than did IDC (P < 0.0001) and PanIN (P = 0.0031), although S100P expression did not differ between IDC and PanIN (P = 0.077). In pancreatic juice analyses, cancer and IPMN juice expressed significantly higher levels of S100P than did pancreatitis juice (both P < 0.0001). Receiver operating characteristic curve analyses revealed that measurement of S100P in pancreatic juice was useful for discriminating neoplastic disease from chronic pancreatitis (area under the curve = 0.837; 95{\%} confidence interval, 0.749-0.903). Conclusion: S100P may be an early developmental marker of pancreatic carcinogenesis, and measurement of S100P in pancreatic juice may be useful for early detection of pancreatic cancer or screening of early pancreatic carcinogenesis.",
author = "Kenoki Ohuchida and Kazuhiro Mizumoto and Takuya Egami and Hiroshi Yamaguchi and Kei Fujii and Hiroyuki Konomi and Eishi Nagai and Koji Yamaguchi and Masazumi Tsuneyoshi and Masao Tanaka",
year = "2006",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-06-0298",
language = "English",
volume = "12",
pages = "5411--5416",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - S100P is an early developmental marker of pancreatic carcinogenesis

AU - Ohuchida, Kenoki

AU - Mizumoto, Kazuhiro

AU - Egami, Takuya

AU - Yamaguchi, Hiroshi

AU - Fujii, Kei

AU - Konomi, Hiroyuki

AU - Nagai, Eishi

AU - Yamaguchi, Koji

AU - Tsuneyoshi, Masazumi

AU - Tanaka, Masao

PY - 2006/9/15

Y1 - 2006/9/15

N2 - Purpose: Our goal was to clarify the involvement and clinical significance of S100P in pancreatic carcinogenesis. Experimental Design: We examined S100P expression in 45 bulk pancreatic tissues; in microdissected cells, including invasive ductal carcinoma (IDC) cells (20 sections), pancreatic intraepithelial neoplasia (PanIN) cells (12 sections), intraductal papillary mucinous neoplasm (IPMN) cells (19 sections), and normal epithelial cells (11 sections); and in pancreatic juice samples from 99 patients with pancreatic diseases (32 cancer, 35 IPMN, and 32 chronic pancreatitis samples). We used quantitative real-time reverse transcription-PCR with gene-specific priming to measure S100P in these various types of samples. Results: In bulk tissue analyses, pancreatic cancer and IPMN expressed significantly higher levels of S100P than did nonneoplastic pancreas (P < 0.017 and P = 0.0013, respectively). Microdissection analyses revealed that IPMN expressed significantly higher levels of S100P than did IDC (P < 0.0001) and PanIN (P = 0.0031), although S100P expression did not differ between IDC and PanIN (P = 0.077). In pancreatic juice analyses, cancer and IPMN juice expressed significantly higher levels of S100P than did pancreatitis juice (both P < 0.0001). Receiver operating characteristic curve analyses revealed that measurement of S100P in pancreatic juice was useful for discriminating neoplastic disease from chronic pancreatitis (area under the curve = 0.837; 95% confidence interval, 0.749-0.903). Conclusion: S100P may be an early developmental marker of pancreatic carcinogenesis, and measurement of S100P in pancreatic juice may be useful for early detection of pancreatic cancer or screening of early pancreatic carcinogenesis.

AB - Purpose: Our goal was to clarify the involvement and clinical significance of S100P in pancreatic carcinogenesis. Experimental Design: We examined S100P expression in 45 bulk pancreatic tissues; in microdissected cells, including invasive ductal carcinoma (IDC) cells (20 sections), pancreatic intraepithelial neoplasia (PanIN) cells (12 sections), intraductal papillary mucinous neoplasm (IPMN) cells (19 sections), and normal epithelial cells (11 sections); and in pancreatic juice samples from 99 patients with pancreatic diseases (32 cancer, 35 IPMN, and 32 chronic pancreatitis samples). We used quantitative real-time reverse transcription-PCR with gene-specific priming to measure S100P in these various types of samples. Results: In bulk tissue analyses, pancreatic cancer and IPMN expressed significantly higher levels of S100P than did nonneoplastic pancreas (P < 0.017 and P = 0.0013, respectively). Microdissection analyses revealed that IPMN expressed significantly higher levels of S100P than did IDC (P < 0.0001) and PanIN (P = 0.0031), although S100P expression did not differ between IDC and PanIN (P = 0.077). In pancreatic juice analyses, cancer and IPMN juice expressed significantly higher levels of S100P than did pancreatitis juice (both P < 0.0001). Receiver operating characteristic curve analyses revealed that measurement of S100P in pancreatic juice was useful for discriminating neoplastic disease from chronic pancreatitis (area under the curve = 0.837; 95% confidence interval, 0.749-0.903). Conclusion: S100P may be an early developmental marker of pancreatic carcinogenesis, and measurement of S100P in pancreatic juice may be useful for early detection of pancreatic cancer or screening of early pancreatic carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=33749364644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749364644&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-0298

DO - 10.1158/1078-0432.CCR-06-0298

M3 - Article

C2 - 17000674

AN - SCOPUS:33749364644

VL - 12

SP - 5411

EP - 5416

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -